Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar ...

Alkermes’ set of proprietary products has generated combined sales worth $1.08 billion in 2024, reflecting an increase of 18% on a year-over-year basis. The company expects to record $1.09-$1.15 ...